ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
65,500
-500 (-0.76%)
Jun 27, 2025, 3:30 PM KST
193.72%
Market Cap 3.41T
Revenue (ttm) 27.63B
Net Income (ttm) -71.71B
Shares Out 48.53M
EPS (ttm) -1,489.50
PE Ratio n/a
Forward PE 82.65
Dividend n/a
Ex-Dividend Date n/a
Volume 546,308
Average Volume 857,516
Open 65,400
Previous Close 66,000
Day's Range 64,800 - 67,800
52-Week Range 21,900 - 84,000
Beta 0.82
RSI 39.75
Earnings Date Aug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.